IFNγ signaling integrity in colorectal cancer immunity and immunotherapy

The majority of colorectal cancer patients are not responsive to immune checkpoint blockade (ICB). The interferon gamma (IFNγ) signaling pathway drives spontaneous and ICB-induced antitumor immunity. In this review, we summarize recent advances in the epigenetic, genetic, and functional integrity of...

Full description

Saved in:
Bibliographic Details
Published in:Cellular & molecular immunology 2022-01, Vol.19 (1), p.23-32
Main Authors: Du, Wan, Frankel, Timothy L., Green, Michael, Zou, Weiping
Format: Article
Language:English
Subjects:
631/250/251/1574
692/4028
Antibodies
Apoptosis
Biomedical and Life Sciences
Biomedicine
Cancer
Clinical trials
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - genetics
Colorectal Neoplasms - therapy
Epigenetics
Ferroptosis
Humans
Immune checkpoint
Immunology
Immunotherapy
Interferon-gamma - metabolism
Medical Microbiology
Microbiology
Microenvironments
Patients
Protein Transport
Review
Review Article
Signal Transduction
Tumor Microenvironment
Vaccine
γ-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c474t-e0a6086165080d254ec95ba6e29c56319608a8c72602431c975e75fba049ac463
cites cdi_FETCH-LOGICAL-c474t-e0a6086165080d254ec95ba6e29c56319608a8c72602431c975e75fba049ac463
container_end_page 32
container_issue 1
container_start_page 23
container_title Cellular & molecular immunology
container_volume 19
creator Du, Wan
Frankel, Timothy L.
Green, Michael
Zou, Weiping
description The majority of colorectal cancer patients are not responsive to immune checkpoint blockade (ICB). The interferon gamma (IFNγ) signaling pathway drives spontaneous and ICB-induced antitumor immunity. In this review, we summarize recent advances in the epigenetic, genetic, and functional integrity of the IFNγ signaling pathway in the colorectal cancer microenvironment and its immunological relevance in the therapeutic efficacy of and resistance to ICB. Moreover, we discuss how to target IFNγ signaling to inform novel clinical trials to treat patients with colorectal cancer.
doi_str_mv 10.1038/s41423-021-00735-3
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8752802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2618748500</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-e0a6086165080d254ec95ba6e29c56319608a8c72602431c975e75fba049ac463</originalsourceid><addsrcrecordid>eNp9kc1O3DAUha0KVKa0L9AFisSGTej1v7OphFChI6GygbXl8XgyRok92AnSPBfv0WfCkIH-LFjZvue759o-CH3FcIqBqm-ZYUZoDQTXAJLymn5AMwKMlBIRe2iGhSS1FAofoE853wFwxST7iA4oo4rzhszQfH7x6_djlX0bTOdDW_kwuDb5YVt2lY1dTM4OpqusCdalyvf9GJ5VE5bTIQ5rl8xm-xntr0yX3ZfdeohuL37cnP-sr64v5-dnV7Uts4fagRGgBBYcFCwJZ842fGGEI43lguKmqEZZSQQQRrFtJHeSrxYGWGMsE_QQfZ98N-Oid0vrwpBMpzfJ9yZtdTRe_6sEv9ZtfNBKcqKAFIOTnUGK96PLg-59tq7rTHBxzJpwgZnihMmCHv-H3sUxlZ8qlMBKFgygUGSibIo5J7d6uwwG_ZyUnpLSJSn9kpSmpeno72e8tbxGUwA6AblIoXXpz-x3bJ8A1XKe_g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618748500</pqid></control><display><type>article</type><title>IFNγ signaling integrity in colorectal cancer immunity and immunotherapy</title><source>Springer Link</source><source>PubMed Central</source><creator>Du, Wan ; Frankel, Timothy L. ; Green, Michael ; Zou, Weiping</creator><creatorcontrib>Du, Wan ; Frankel, Timothy L. ; Green, Michael ; Zou, Weiping</creatorcontrib><description>The majority of colorectal cancer patients are not responsive to immune checkpoint blockade (ICB). The interferon gamma (IFNγ) signaling pathway drives spontaneous and ICB-induced antitumor immunity. In this review, we summarize recent advances in the epigenetic, genetic, and functional integrity of the IFNγ signaling pathway in the colorectal cancer microenvironment and its immunological relevance in the therapeutic efficacy of and resistance to ICB. Moreover, we discuss how to target IFNγ signaling to inform novel clinical trials to treat patients with colorectal cancer.</description><identifier>ISSN: 1672-7681</identifier><identifier>ISSN: 2042-0226</identifier><identifier>EISSN: 2042-0226</identifier><identifier>DOI: 10.1038/s41423-021-00735-3</identifier><identifier>PMID: 34385592</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/251/1574 ; 692/4028 ; Antibodies ; Apoptosis ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Clinical trials ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - therapy ; Epigenetics ; Ferroptosis ; Humans ; Immune checkpoint ; Immunology ; Immunotherapy ; Interferon-gamma - metabolism ; Medical Microbiology ; Microbiology ; Microenvironments ; Patients ; Protein Transport ; Review ; Review Article ; Signal Transduction ; Tumor Microenvironment ; Vaccine ; γ-Interferon</subject><ispartof>Cellular &amp; molecular immunology, 2022-01, Vol.19 (1), p.23-32</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-e0a6086165080d254ec95ba6e29c56319608a8c72602431c975e75fba049ac463</citedby><cites>FETCH-LOGICAL-c474t-e0a6086165080d254ec95ba6e29c56319608a8c72602431c975e75fba049ac463</cites><orcidid>0000-0001-7952-3549</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752802/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752802/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34385592$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Du, Wan</creatorcontrib><creatorcontrib>Frankel, Timothy L.</creatorcontrib><creatorcontrib>Green, Michael</creatorcontrib><creatorcontrib>Zou, Weiping</creatorcontrib><title>IFNγ signaling integrity in colorectal cancer immunity and immunotherapy</title><title>Cellular &amp; molecular immunology</title><addtitle>Cell Mol Immunol</addtitle><addtitle>Cell Mol Immunol</addtitle><description>The majority of colorectal cancer patients are not responsive to immune checkpoint blockade (ICB). The interferon gamma (IFNγ) signaling pathway drives spontaneous and ICB-induced antitumor immunity. In this review, we summarize recent advances in the epigenetic, genetic, and functional integrity of the IFNγ signaling pathway in the colorectal cancer microenvironment and its immunological relevance in the therapeutic efficacy of and resistance to ICB. Moreover, we discuss how to target IFNγ signaling to inform novel clinical trials to treat patients with colorectal cancer.</description><subject>631/250/251/1574</subject><subject>692/4028</subject><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Clinical trials</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - therapy</subject><subject>Epigenetics</subject><subject>Ferroptosis</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Interferon-gamma - metabolism</subject><subject>Medical Microbiology</subject><subject>Microbiology</subject><subject>Microenvironments</subject><subject>Patients</subject><subject>Protein Transport</subject><subject>Review</subject><subject>Review Article</subject><subject>Signal Transduction</subject><subject>Tumor Microenvironment</subject><subject>Vaccine</subject><subject>γ-Interferon</subject><issn>1672-7681</issn><issn>2042-0226</issn><issn>2042-0226</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kc1O3DAUha0KVKa0L9AFisSGTej1v7OphFChI6GygbXl8XgyRok92AnSPBfv0WfCkIH-LFjZvue759o-CH3FcIqBqm-ZYUZoDQTXAJLymn5AMwKMlBIRe2iGhSS1FAofoE853wFwxST7iA4oo4rzhszQfH7x6_djlX0bTOdDW_kwuDb5YVt2lY1dTM4OpqusCdalyvf9GJ5VE5bTIQ5rl8xm-xntr0yX3ZfdeohuL37cnP-sr64v5-dnV7Uts4fagRGgBBYcFCwJZ842fGGEI43lguKmqEZZSQQQRrFtJHeSrxYGWGMsE_QQfZ98N-Oid0vrwpBMpzfJ9yZtdTRe_6sEv9ZtfNBKcqKAFIOTnUGK96PLg-59tq7rTHBxzJpwgZnihMmCHv-H3sUxlZ8qlMBKFgygUGSibIo5J7d6uwwG_ZyUnpLSJSn9kpSmpeno72e8tbxGUwA6AblIoXXpz-x3bJ8A1XKe_g</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Du, Wan</creator><creator>Frankel, Timothy L.</creator><creator>Green, Michael</creator><creator>Zou, Weiping</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7952-3549</orcidid></search><sort><creationdate>20220101</creationdate><title>IFNγ signaling integrity in colorectal cancer immunity and immunotherapy</title><author>Du, Wan ; Frankel, Timothy L. ; Green, Michael ; Zou, Weiping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-e0a6086165080d254ec95ba6e29c56319608a8c72602431c975e75fba049ac463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>631/250/251/1574</topic><topic>692/4028</topic><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Clinical trials</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - therapy</topic><topic>Epigenetics</topic><topic>Ferroptosis</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Interferon-gamma - metabolism</topic><topic>Medical Microbiology</topic><topic>Microbiology</topic><topic>Microenvironments</topic><topic>Patients</topic><topic>Protein Transport</topic><topic>Review</topic><topic>Review Article</topic><topic>Signal Transduction</topic><topic>Tumor Microenvironment</topic><topic>Vaccine</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Du, Wan</creatorcontrib><creatorcontrib>Frankel, Timothy L.</creatorcontrib><creatorcontrib>Green, Michael</creatorcontrib><creatorcontrib>Zou, Weiping</creatorcontrib><collection>Springer Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cellular &amp; molecular immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Du, Wan</au><au>Frankel, Timothy L.</au><au>Green, Michael</au><au>Zou, Weiping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IFNγ signaling integrity in colorectal cancer immunity and immunotherapy</atitle><jtitle>Cellular &amp; molecular immunology</jtitle><stitle>Cell Mol Immunol</stitle><addtitle>Cell Mol Immunol</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>19</volume><issue>1</issue><spage>23</spage><epage>32</epage><pages>23-32</pages><issn>1672-7681</issn><issn>2042-0226</issn><eissn>2042-0226</eissn><abstract>The majority of colorectal cancer patients are not responsive to immune checkpoint blockade (ICB). The interferon gamma (IFNγ) signaling pathway drives spontaneous and ICB-induced antitumor immunity. In this review, we summarize recent advances in the epigenetic, genetic, and functional integrity of the IFNγ signaling pathway in the colorectal cancer microenvironment and its immunological relevance in the therapeutic efficacy of and resistance to ICB. Moreover, we discuss how to target IFNγ signaling to inform novel clinical trials to treat patients with colorectal cancer.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>34385592</pmid><doi>10.1038/s41423-021-00735-3</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-7952-3549</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1672-7681
ispartof Cellular & molecular immunology, 2022-01, Vol.19 (1), p.23-32
issn 1672-7681
2042-0226
2042-0226
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8752802
source Springer Link; PubMed Central
subjects 631/250/251/1574
692/4028
Antibodies
Apoptosis
Biomedical and Life Sciences
Biomedicine
Cancer
Clinical trials
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - genetics
Colorectal Neoplasms - therapy
Epigenetics
Ferroptosis
Humans
Immune checkpoint
Immunology
Immunotherapy
Interferon-gamma - metabolism
Medical Microbiology
Microbiology
Microenvironments
Patients
Protein Transport
Review
Review Article
Signal Transduction
Tumor Microenvironment
Vaccine
γ-Interferon
title IFNγ signaling integrity in colorectal cancer immunity and immunotherapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T12%3A56%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IFN%CE%B3%20signaling%20integrity%20in%20colorectal%20cancer%20immunity%20and%20immunotherapy&rft.jtitle=Cellular%20&%20molecular%20immunology&rft.au=Du,%20Wan&rft.date=2022-01-01&rft.volume=19&rft.issue=1&rft.spage=23&rft.epage=32&rft.pages=23-32&rft.issn=1672-7681&rft.eissn=2042-0226&rft_id=info:doi/10.1038/s41423-021-00735-3&rft_dat=%3Cproquest_pubme%3E2618748500%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-e0a6086165080d254ec95ba6e29c56319608a8c72602431c975e75fba049ac463%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2618748500&rft_id=info:pmid/34385592&rfr_iscdi=true